GlassScriptPhysician profile
Danilo V Delcampo
NPI 1801893052
$12,709.00
in general payments reported to CMS, 2019-2025
32 companies · $1,890 in 2025
The $1,890 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,708 · 2020: $1,342 · 2021: $1,780 · 2022: $1,986 · 2023: $2,272 · 2024: $1,732 · 2025: $1,890.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,962 · Consulting Fee: $700 · Education: $232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,961.52 |
| Consulting Fee | $700.00 |
| Education | $231.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,348.54 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $1,308.41 | 2020-2025 | Tremfya, Simponi Aria, Stelara |
| Mayne Pharma Commercial LLC | $1,300.35 | 2019-2025 | |
| Amgen INC. | $1,179.32 | 2019-2025 | Otezla, Otezla |
| Pfizer INC. | $938.63 | 2019-2025 | |
| Medimetriks Pharmaceuticals, INC. | $855.74 | 2020-2024 | Neo-Synalar, Tovet (Emollient Formulation) |
| Leo Pharma INC. | $675.58 | 2021-2025 | Adbry |
| Sun Pharmaceutical Industries INC. | $660.76 | 2019-2024 | Ilumya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $458.99 | 2020-2025 | Arazlo, Jublia, Cabtreo |
| Ucb, INC. | $450.45 | 2019-2025 | Bimzelx |
| Celgene Corporation | $310.45 | 2019 | |
| Merz North America, INC. | $286.03 | 2021-2022 | |
| Genzyme Corporation | $268.72 | 2019-2023 | |
| Lilly USA, LLC | $261.63 | 2019-2025 | Taltz, Ebglyss |
| Novartis Pharmaceuticals Corporation | $211.25 | 2019-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $165.37 | 2020-2025 | Dupixent |
| Vyne Pharmaceuticals INC. | $144.77 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $139.57 | 2022-2024 | Sotyktu |
| Incyte Corporation | $109.28 | 2024-2025 | Opzelura |
| Janssen Scientific Affairs, LLC | $96.15 | 2021 | |
| Epi Health, LLC | $77.31 | 2019-2022 | |
| Botanix Sb INC | $72.31 | 2025 | Sofdra |
| Sanofi-Aventis U.S. LLC | $69.99 | 2021 | |
| Sandoz INC. | $65.84 | 2020-2021 | |
| Encore Dermatology INC. | $59.84 | 2019-2020 | |
| Journey Medical Corporation | $53.08 | 2019-2022 | |
| Galderma Laboratories, L.P. | $45.72 | 2019-2024 | |
| Almirall LLC | $31.17 | 2019-2020 | |
| Dermavant Sciences, INC. | $20.59 | 2023 | Vtama |
| Aclaris Therapeutics, INC. | $16.66 | 2019 | |
| Mission Pharmacal Company | $16.63 | 2019 | |
| Strata Skin Sciences, INC. | $9.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danilo Delcampo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.